Elan bids to get MS drug back on sale

ELAN is to make a fresh attempt to get its multiple sclerosis drug Tysabri back on the market.

The company, which withdrew Tysabri from sale in February when it emerged two people who took the drug developed the fatal disease PML, said it will submit an application to US drug regulator, the Food & Drug Administration (FDA), in the coming weeks to have the treatment cleared for sale.

It also intends to submit a safety evaluation of Tysabri for the treatment of the debilitating Crohn's disease and rheumatoid arthritis.